

11/29/01

J1130 U.S. PTO

S&amp;H Form: PTO/SB/05 (2/01)

**UTILITY  
PATENT APPLICATION****TRANSMITTAL**

(Only for original applications)

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

Attorney Docket No. 1546.1007

First Named Inventor or Application Identifier:  
Ji-Won YOON et al.

Express Mail Label No.

ADDRESS TO:

**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231**

J1130 U.S. PTO

09/995829

11/29/01

11/29/01

1. ☒ Fee Transmittal Form
2. ☒ Specification, Claims & Abstract .....[Total Pages: 29]
3. ☒ Drawing(s) (35 USC 113) .....[ Total Sheets: 7 ] [FIGS. 1-10 ]
4. ☒ Oath or Declaration .....[ Total Pages: 2 ]
  - a. ☒ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))
    - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ Verified Statement Claiming Small Entity Status
6. ☐ Application Data Sheet. See 37 C.F.R. 1.76
7. ☐ CD-Rom or CD-R in duplicate, large table or Computer Program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☒ Assignment (cover sheet & document(s)) to Korea Greencross Corporation of Yongin-si, Republic of Korea  
☒ for publication of assignee information under 37 CFR 1.215(b)
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☒ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Request and Certification for Nonpublication under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent
17. ☐ Other:

**18. CORRESPONDENCE ADDRESS**

21171

PATENT TRADEMARK OFFICE

<b>NEW APPLICATION FEE TRANSMITTAL</b>		Attorney Docket No.	1546.1007
		Application Number	Unassigned
		Filing Date	November 29, 2001
AMOUNT ENCLOSED	\$ 780.00	First Named Inventor	Ji-Won YOON et al.

FEE CALCULATION (fees effective 10/01/00)					
CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS	11 - 20 =	0	X \$ 18.00 =	\$ 0.00
	INDEPENDENT CLAIMS	2 - 3 =	0	X \$ 84.00 =	0.00
	MULTIPLE DEPENDENT CLAIMS (any number; if applicable)			+ \$280.00 =	
				BASIC FILING FEE	740.00
				Total of above Calculations =	\$ 740.00
Surcharge for late filing fee, Oath or Declaration (37 CFR 1.53(f)) (\$130.00)					
Reduction by 50% for filing by small entity (37 CFR 1.27).					
				TOTAL FILING FEE =	\$ 740.00
Surcharge for filing non-English language application (\$130.00; 37 CFR 1.52(d))					
Recordation of Assignment (\$40.00; 37 CFR 1.21(h))					40.00
				TOTAL FEES DUE =	\$ 780.00


  

METHOD OF PAYMENT	
<input checked="" type="checkbox"/>	Check enclosed as payment.
<input type="checkbox"/>	Charge "TOTAL FEES DUE" to the Deposit Account No. below.
<input type="checkbox"/>	No payment is enclosed and no charges to the Deposit Account are authorized at this time (unless specifically required to obtain a filing date).

GENERAL AUTHORIZATION	
<input checked="" type="checkbox"/>	If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:
Deposit Account No.	19-3935
Deposit Account Name	STAAS & HALSEY LLP
<input checked="" type="checkbox"/>	The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

SUBMITTED BY: STAAS & HALSEY LLP			
Typed Name	Michael D. Stein	Reg. No.	37,240
Signature		Date	11/29/01

F0627 " 623550

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ji-Won YOON et al.

Application No.: Unassigned

Group Art Unit: Unassigned

Filed: November 29, 2001

Examiner: Unassigned

For: RECOMBINANT VACCINIA INCORPORATED WITH GENE CODING GLUTAMIC ACID  
DECARBOXYLASE AND VACCINE FOR PREVENTING TYPE 1 DIABETES MELLITUS  
COMPRISING THE SAME

SUBMISSION OF PHOTOGRAPHS

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed are three copies of photographs which are being filed to further enhance the quality of the black and white drawings submitted concurrently herewith in the above-identified application. The first set of photographs correspond to FIGS. 1 and 2 and the second set of photographs correspond to FIGS. 5a through 5f.

If there are any formal matters remaining after this response, the Examiner is requested to telephone the undersigned to attend to these matters.

If any payments are required in connection with the filing of this paper, please charge same to our Deposit Account No.19-3935.


Respectfully submitted,

STAAS & HALSEY LLP

Date:

11/29/01

By:

  
Michael D. Stein  
Registration No. 37,240

700 11th Street, N.W., Ste. 500  
Washington, D.C. 20001  
(202) 434-1500

100-525660